iVeena Completes Phase I/IIa Study of IVMED-10 for Post-Cataract Inflammation

November 17, 2017: By Jon Swedien

iVeenaiVeena Delivery Systems has successfully completed a pilot clinical trial for its lead product, IVMED-10, a bioerodible implant that treats pain and inflammation after cataract surgery, the Salt Lake City-based company announced Nov. 8.

IVMED-10 is a sustained release implant, based on the company’s intracapsular drug delivery platform, that delivers dexamethasone for two weeks. The device is placed in the lens capsule during the time of cataract surgery. It is intended for patients undergoing routine cataract extraction, iVeena said.

Eight patients were enrolled in the Phase I/IIa, single-site, single-arm, open-label clinical study. iVeena said an independent clinical trial report found IVMED-10 was safe and effective for the control of inflammation typically observed following cataract surgery. Retinal thickness outcomes were comparable to published data of nonsteroidal anti-inflammatory drugs and steroid standard of care therapy. All adverse events, including elevated intraocular pressure, corneal edema, and pain, were transient in nature. All patients had 20/25 best-corrected visual acuity or better at the end of the study, iVeena said.

iVeena has additional clinical studies of IVMED-10 planned for Q1-2018.

The company is also developing IVMED-20, a sustained release implant that delivers dexamethasone for six weeks. The product is placed in the lens capsule at the time of cataract surgery and is intended for patients that are at risk of developing retinal thickening in association with cataract extraction.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022